Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2020 09:00 ET | Source: CohBar, Inc.

CohBar to Present at the BIO Investor Forum

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 29, 2020 16:05 ET | Source: CohBar, Inc.

CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 10, 2020 16:05 ET | Source: CohBar, Inc.

CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 03, 2020 08:45 ET | Source: CohBar, Inc.

CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
August 28, 2020 16:05 ET | Source: CohBar, Inc.

CohBar Announces Closing of Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
August 26, 2020 08:30 ET | Source: CohBar, Inc.

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
August 25, 2020 16:55 ET | Source: CohBar, Inc.

CohBar Announces Proposed Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
August 24, 2020 09:00 ET | Source: CohBar, Inc.

CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
August 13, 2020 16:03 ET | Source: CohBar, Inc.

CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update

New positive preliminary preclinical results in ARDS modelCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:...
August 05, 2020 09:00 ET | Source: CohBar, Inc.

CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference

MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...